Drug Profile
Ibutamoren - Lumos Pharma/Merck
Alternative Names: Ibutamoren mesilate; Ibutamoren mesylate; L 163191; LUM-201; MK-0677; MK-677; OratropeLatest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Lumos Pharma; Massachusetts General Hospital; Merck & Co
- Class Antidementias; Hepatoprotectants; Indoles; Osteoporosis therapies; Small molecules; Spiro compounds
- Mechanism of Action Growth hormone releasing factor agonists; Insulin-like growth factor I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic fatty liver disease; Somatotropin deficiency
- Phase I Turner's syndrome
- Discontinued Alzheimer's disease; Fibromyalgia; Fracture; Postmenopausal osteoporosis; Sarcopenia
Most Recent Events
- 12 Apr 2024 Lumos Pharma has patent protection for Ibutamoren in Canada before April 2024 (Lumos Pharma, Form 10-K)
- 12 Apr 2024 Lumos Pharma has patent protection for method of use of Ibutamoren for growth hormone deficiency disorders in USA before April 2024 (Lumos Pharma, Form 10-K)
- 12 Apr 2024 Lumos Pharma has patents pending for method of use of Ibutamoren for growth hormone deficiency disorders in many countries (Lumos Pharma, Form 10-K)